Observational studyThe Journal of international medical research2025
Prevalence and clinicopathological features of human epidermal growth factor receptor-2-low breast cancers: A single-center experience.
Observational study in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveHuman epidermal growth factor receptor-2-low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1+ or immunohistochemistry score 2+ without amplification, has been proposed as a distinct subgroup. This study investigated the prevalence and clinicopathological characteristics of human epidermal growth factor receptor-2-low breast cancers.MethodsA retrospective observational cohort study was conducted on patients diagnosed with invasive breast carcinoma between 2021 and 2023 at a single tertiary center. Data on histological type, tumor grade, human epidermal growth factor receptor-2 status, and Ki-67 proliferation index were collected.ResultsAmong the 181 patients who were included, 54.7% were classified as human epidermal growth factor receptor-2-low, 27.6% as human epidermal growth factor receptor-2-negative, and 17.7% as human epidermal growth factor receptor-2-positive. Human epidermal growth factor receptor-2-low tumors were predominantly those classified into grade 2 (69.7%). The mean age of patients with human epidermal growth factor receptor-2-low tumors was 60 years. The Ki-67 index was significantly lower in human epidermal growth factor receptor-2-low tumors than in human epidermal growth factor receptor-2-positive and human epidermal growth factor receptor-2-negative groups (p = 0.001). No significant differences were observed in the rates of axillary lymph node metastasis among the groups (p = 0.13).ConclusionHuman epidermal growth factor receptor-2-low breast cancers constitute a significant proportion of breast cancer cases and are associated with distinct clinicopathological features, including high estrogen reception positivity and lower Ki-67 proliferation rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.